Insulin Degludec

Active ingredient: Insulin Degludec

In short: Insulin Degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus. Limitations of Use •Not recommended for the treatment of diabetic ketoacidosis.

Forms & strengthsInjection: Available as a clear and colorless solution: •100 units/mL (U-100): 3 mL single-patient-use FlexTouch prefilled pen •100 units/mL (U-100): 10 mL multiple-dose vial •200 units/mL (U-200): 3 mL single-patient-use FlexTouch prefilled pen
LabelNovo Nordisk Pharma, Inc.
Label updatedJun 17, 2026

What is Insulin Degludec used for?

Insulin Degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.

Limitations of Use

•Not recommended for the treatment of diabetic ketoacidosis.

Insulin Degludec dosage

•Always check insulin labels before administration. This product is Tresiba (insulin degludec) .

•Inspect visually for particulate matter and discoloration. Only use Insulin Degludec if the solution appears clear and colorless.

•Inject Insulin Degludec subcutaneously into the thigh, upper arm, or abdomen.

•Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis .

•During changes to a patient’s insulin regimen, increase the frequency of blood glucose monitoring .

•For pediatric patients requiring less than 5 units of Insulin Degludec each day, use the Insulin Degludec U-100 vial.

•DO NOT administer Insulin Degludec intravenously or in an insulin infusion pump.

•DO NOT dilute or mix Insulin Degludec with any other insulin or solution.

•DO NOT transfer Insulin Degludec from the Insulin Degludec FlexTouch pen into a syringe for administration .

•Use Insulin Degludec FlexTouch pens with caution in patients with visual impairment that may rely on audible clicks to dial their dose.

•Insulin Degludec is available in 2 concentrations (U-100 and U-200):

oInsulin Degludec U-100 is available, as a single-patient use FlexTouch pen and multiple-dose vial.

▪The FlexTouch pen delivers doses in 1 unit increments and can deliver up to 80 units in a single injection.

oInsulin Degludec U-200 is available as a single-patient-use FlexTouch pen.

▪The FlexTouch pen delivers doses in 2 unit increments and can deliver up to 160 units in a single injection.

•DO NOT perform dose conversion when using the Insulin Degludec U-100 or U-200 FlexTouch pens. The dose window shows the number of insulin units to be delivered and no conversion is needed.

•In adults, inject Insulin Degludec subcutaneously once-daily at any time of day.

•In pediatric patients inject Insulin Degludec subcutaneously once-daily at the same time every day.

•Individualize and titrate the dose of Insulin Degludec based on the patient’s metabolic needs, blood glucose monitoring results, and glycemic control goal.

•The recommended days between dose increases are 3 to 4 days.

•Dose adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), changes in renal or hepatic function or during acute illness to minimize the risk of hypoglycemia or hyperglycemia .

•For adult patients, instruct patients who miss a dose of Insulin Degludec to inject their daily dose during waking hours upon discovering the missed dose. Instruct patients to ensure that at least 8 hours have elapsed between consecutive Insulin Degludec injections. …

How to take Insulin Degludec — instructions & advice from the label

Advise the patient and/or caregiver to read the FDA-approved patient labeling (Patient Information and Instructions for Use). There are separate Instructions for Use for the Vials and FlexTouch Pens.

Never Share an Insulin Degludec FlexTouch Pen, Needle, or Insulin Syringe Between Patients

Advise patients that they should never share an Insulin Degludec FlexTouch pen device with another person, even if the needle is changed. Advise patients using Insulin Degludec vials not to share needles or insulin syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens .

Hyperglycemia or Hypoglycemia

Inform patients that hypoglycemia is the most common adverse reaction with insulin. Inform patients of the symptoms of hypoglycemia (e.g., impaired ability to concentrate and react). This may present a risk in situations where these abilities are especially important, such as driving or operating other machinery. Advise patients who have frequent hypoglycemia or reduced or absent warning signs of hypoglycemia to use caution when driving or operating machinery . …

Warnings & precautions

Do not take this medicine if: Insulin Degludec is contraindicated:

•During episodes of hypoglycemia .

•In patients with hypersensitivity to insulin degludec or any of the excipients in Insulin Degludec .

Insulin Degludec FlexTouch disposable prefilled pens should never be shared between patients, even if the needle is changed. Patients using Insulin Degludec vials should never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.

Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia .

Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. For patients with type 2 diabetes, adjustments in concomitant anti-diabetic treatment may be needed .

Hypoglycemia is the most common adverse reaction of insulin, including Insulin Degludec . Severe hypoglycemia can cause seizures, may be life-threatening or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place the patient and others at risk in situations where these abilities are important (e.g., driving or operating other machinery). Insulin Degludec, or any insulin, should not be used during episodes of hypoglycemia . …

Insulin Degludec side effects

The following adverse reactions are also discussed elsewhere:

•Hypoglycemia

•Hypoglycemia due to Medication errors

•Hypersensitivity reactions

•Hypokalemia

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of Insulin Degludec in subjects with type 1 diabetes or type 2 diabetes was evaluated in nine trials of 6-12 month duration in adults and in one trial of 12-month duration in pediatric patients 1 year of age and older with type 1 diabetes. The cardiovascular safety of Insulin Degludec was evaluated in one double-blinded, event-driven trial of 2-year median duration in patients with type 2 diabetes at high risk of cardiovascular events .

The data in Table 1 reflect the exposure of 1102 adults with type 1 diabetes to Insulin Degludec with a mean exposure duration to Insulin Degludec of 34 weeks in three open-label trials; Study A, B and C . The mean age was 43 years and 1% were older than 75 years. Fifty-seven percent were male, 81% were White, 2% were Black or African American and 4% were Hispanic. The mean body mass index (BMI) was 26 kg/m2. The mean duration of diabetes was 18 years and the mean HbA1c at baseline was 7.8%. …

Drug interactions

Table 5 includes clinically significant drug interactions with Insulin Degludec.

Table 5: Clinically Significant Drug Interactions with Insulin Degludec

Drugs That May Increase the Risk of Hypoglycemia

Drugs: | Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors.

Intervention: | Dosage reductions and increased frequency of glucose monitoring may be required when Insulin Degludec is co-administered with these drugs.

Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec

Drugs: | Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.

Intervention: | Dosage increases and increased frequency of glucose monitoring may be required when Insulin Degludec is co-administered with these drugs. …

About this medicine

Insulin degludec is a long-acting basal human insulin analog for subcutaneous injection produced by a process that includes expression of recombinant DNA in Saccharomyces cerevisiae followed by chemical modification.

Insulin degludec differs from human insulin in that the amino acid threonine in position B30 has been omitted and a side-chain consisting of glutamic acid and a C16 fatty acid has been attached (chemical name: LysB29(Nε-hexadecandioyl-γ-Glu) des(B30) human insulin). Insulin degludec has a molecular formula of C274H411N65O81S6 and a molecular weight of 6.104 kDa. It has the following structure:

Figure 1: Structural Formula of Insulin Degludec

Insulin Degludec injection is a sterile, aqueous, clear, and colorless solution available as 100 units/mL (U-100) or 200 units/mL (U-200) for subcutaneous use.

For the 100 units/mL solution, each mL contains 100 units of insulin degludec and glycerin (19.6 mg), metacresol (1.72 mg), phenol (1.5 mg), zinc (32.7 mcg), and Water for Injection, USP. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID c1be283d-4b1d-4996-b2a7-4488dbff3037. Read the full official label on DailyMed.

Related medicines

Atorvastatin Metformin Losartan Semaglutide Insulin Glargine Empagliflozin Glipizide Insulin Lispro